Skip to main content

Sero-profiling identifies ibrutinib as a treatment option for young adults with B-cell acute lymphoblastic leukaemia (2019)
Journal Article
Guinn, B., Jordaens, S., Cooksey, L., Coutinho, M., Van Tendeloo, V., Mills, K., & Orchard, K. (in press). Sero-profiling identifies ibrutinib as a treatment option for young adults with B-cell acute lymphoblastic leukaemia. British journal of haematology,

Acute lymphoblastic leukaemia (ALL) is a haematological malignancy that is characterized by the uncontrolled proliferation of immature lymphocytes. 80 % of cases occur in children where ALL is well understood and treated. However it has a devastating... Read More about Sero-profiling identifies ibrutinib as a treatment option for young adults with B-cell acute lymphoblastic leukaemia.

Identification of survivin as a promising target for the immunotherapy of adult B-cell acute lymphoblastic leukemia (2017)
Journal Article
Freire Boullosa, L., Savaliya, P., Bonney, S., Orchard, L., Wickenden, H., Lee, C., …Guinn, B. (2017). Identification of survivin as a promising target for the immunotherapy of adult B-cell acute lymphoblastic leukemia. BMC research notes, 9, 3853-3866. https://doi.org/10.18632/oncotarget.23380

B-cell acute lymphoblastic leukemia (B-ALL) is a rare heterogeneous disease characterized by a block in lymphoid differentiation and a rapid clonal expansion of immature, non-functioning B cells. Adult B-ALL patients have a poor prognosis with less t... Read More about Identification of survivin as a promising target for the immunotherapy of adult B-cell acute lymphoblastic leukemia.